Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
Q3 2022 vs. Q2 2022
How the institutions holding Adma Biologics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 113 | 130 | +17 |
| Shares | 119.2M | 129.8M | +10.5M (+8.8%) |
| Value | $236.0M | $315.4M | +$79.3M (+33.6%) |
New holders (28)
Institutions that held Adma Biologics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (11)
Institutions that held Adma Biologics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Polar Asset Management Partners Inc. | 600,000 | $1.19M |
| Kent Lake Capital LLC | 271,119 | $537.0K |
| Alpine Global Management, LLC | 250,000 | $495.0K |
| Bayesian Capital Management, LP | 55,300 | $109.0K |
| Aquatic Capital Management LLC | 36,000 | $71.0K |
| Eagle Asset Management Inc | 28,833 | $57.0K |
| Wealthstream Advisors, Inc. | 18,000 | $36.0K |
| Viewpoint Capital Management LLC | 13,000 | $26.0K |
| Simplex Trading, LLC | 9,070 | $17.0K |
| Global Wealth Management Investment Advisory, Inc. | 500 | $1.00K |
| Captrust Financial Advisors | 40 | $0 |